211 related articles for article (PubMed ID: 22468182)
1. Patients with hematological malignancies and serological signs of prior resolved hepatitis B.
Marignani M; Gigante E; Begini P; Marzano A; di Fonzo M; Deli I; Gallina S; Cox MC; Delle Fave G
World J Gastrointest Oncol; 2012 Mar; 4(3):37-45. PubMed ID: 22468182
[TBL] [Abstract][Full Text] [Related]
2. Prevention of hepatitis B virus reactivation in patients with hematological malignancies and resolved hepatitis B virus infection: a systematic review and meta-analysis.
Cheung CKM; Law MF; Chao DC; Wong SH; Ho R; Chao ACW; Lai JWY; Chan TYT; Tam MTK; Lau SLF; Tam THC
J Dig Dis; 2020 Mar; 21(3):160-169. PubMed ID: 32040243
[TBL] [Abstract][Full Text] [Related]
3. Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies treated with anticancer therapy.
Law MF; Ho R; Cheung CK; Tam LH; Ma K; So KC; Ip B; So J; Lai J; Ng J; Tam TH
World J Gastroenterol; 2016 Jul; 22(28):6484-500. PubMed ID: 27605883
[TBL] [Abstract][Full Text] [Related]
4. Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management.
Zannella A; Marignani M; Begini P
Viruses; 2019 Sep; 11(9):. PubMed ID: 31540124
[TBL] [Abstract][Full Text] [Related]
5. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy.
Shih CA; Chen WC
World J Clin Cases; 2021 Jul; 9(21):5769-5781. PubMed ID: 34368296
[TBL] [Abstract][Full Text] [Related]
6. Prevention and management of hepatitis B virus reactivation in cancer patients.
Cheung KS; Seto WK; Lai CL; Yuen MF
Hepatol Int; 2016 May; 10(3):407-14. PubMed ID: 26739135
[TBL] [Abstract][Full Text] [Related]
7. Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis.
Paul S; Dickstein A; Saxena A; Terrin N; Viveiros K; Balk EM; Wong JB
Hepatology; 2017 Aug; 66(2):379-388. PubMed ID: 28128861
[TBL] [Abstract][Full Text] [Related]
8. Analysis of baseline hepatitis B virus DNA levels in chronic hepatitis B patients with non-hematological malignancies prior to the initiation of cancer chemotherapy.
Young SH; Wei TH; Lin CC; Chu CJ; Lee FY; Yu MI; Lu RH; Chang CY; Yang PL; Wang MH; Lin HC
Mol Clin Oncol; 2016 Jul; 5(1):165-170. PubMed ID: 27330792
[TBL] [Abstract][Full Text] [Related]
9. Prevalence and chemotherapy-induced reactivation of occult hepatitis B virus among hepatitis B surface antigen negative patients with diffuse large B-cell lymphoma: significance of hepatitis B core antibodies screening.
Elbedewy TA; Elashtokhy HE; Rabee ES; Kheder GE
J Egypt Natl Canc Inst; 2015 Mar; 27(1):11-8. PubMed ID: 25716703
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B in patients with hematological diseases: An update.
Coluccio C; Begini P; Marzano A; Pellicelli A; Imperatrice B; Anania G; Delle Fave G; Marignani M
World J Hepatol; 2017 Sep; 9(25):1043-1053. PubMed ID: 28951776
[TBL] [Abstract][Full Text] [Related]
11. Clinical characteristics and molecular analysis of hepatitis B virus reactivation in hepatitis B surface antigen-negative patients during or after immunosuppressive or cytotoxic chemotherapy.
Hayashi K; Ishigami M; Ishizu Y; Kuzuya T; Honda T; Tachi Y; Ishikawa T; Katano Y; Yoshioka K; Toyoda H; Kumada T; Goto H; Hirooka Y
J Gastroenterol; 2016 Nov; 51(11):1081-1089. PubMed ID: 26943169
[TBL] [Abstract][Full Text] [Related]
12. Multicenter cooperative case survey of hepatitis B virus reactivation by chemotherapeutic agents.
Takahashi H; Ikeda M; Kumada T; Osaki Y; Kondo S; Kusumoto S; Ohkawa K; Nadano S; Furuse J; Kudo M; Ito K; Yokoyama M; Okusaka T; Shimoyama M; Mizokami M
Hepatol Res; 2015 Dec; 45(12):1220-7. PubMed ID: 25627550
[TBL] [Abstract][Full Text] [Related]
13. [Immunosuppressive therapy or chemotherapy-induced reactivation of hepatitis B virus infection].
Sato K
Gan To Kagaku Ryoho; 2011 Feb; 38(2):161-8. PubMed ID: 21368477
[TBL] [Abstract][Full Text] [Related]
14. [A case of hepatitis B virus reactivation in a patient with prior resolved hepatitis B infection during bevacizumab plus FOLFIRI treatment].
Noguchi Y; Tsurushima M; Tamura Y; Aoyama K; Tokuyama Y; Uchiyama K; Shimizu Y
Gan To Kagaku Ryoho; 2013 Nov; 40(11):1561-3. PubMed ID: 24231716
[TBL] [Abstract][Full Text] [Related]
15. Nucleos(t)ide analogues for preventing HBV reactivation in immunosuppressed patients with hematological malignancies: a network meta-analysis.
Zhang MY; Zhu GQ; Zheng JN; Cheng Z; Van Poucke S; Shi KQ; Huang HH; Chen FY; Zheng MH
Expert Rev Anti Infect Ther; 2017 May; 15(5):503-513. PubMed ID: 28317397
[TBL] [Abstract][Full Text] [Related]
16. Virological and clinical characteristics on reactivation of occult hepatitis B in patients with hematological malignancy.
Sugauchi F; Tanaka Y; Kusumoto S; Matsuura K; Sugiyama M; Kurbanov F; Ueda R; Mizokami M
J Med Virol; 2011 Mar; 83(3):412-8. PubMed ID: 21264861
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of prophylactic antiviral therapy and outcomes in HBsAg-negative, anti-HBc-positive patients receiving chemotherapy: a real-life experience.
Papadopoulos N; Deutsch M; Manolakopoulos S; Bitsi C; Michalakeas H; Poulakidas H; Tsironi E; Giannouli S; Papatheodoridis GV; Koskinas J; Pectasides D
Eur J Gastroenterol Hepatol; 2017 Jan; 29(1):56-60. PubMed ID: 27669175
[TBL] [Abstract][Full Text] [Related]
18. Screening, prevention and treatment of viral hepatitis B reactivation in patients with haematological malignancies.
Lalazar G; Rund D; Shouval D
Br J Haematol; 2007 Mar; 136(5):699-712. PubMed ID: 17338776
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of lamivudine prophylaxis in preventing hepatitis B virus reactivation in patients with resolved infection undergoing allogeneic SCT and receiving rituximab.
Zappulo E; Nicolini LA; Di Grazia C; Dominietto A; Lamparelli T; Gualandi F; Caligiuri P; Bruzzone B; Angelucci E; Viscoli C; Mikulska M
Infection; 2019 Feb; 47(1):59-65. PubMed ID: 30232604
[TBL] [Abstract][Full Text] [Related]
20. Updates on management strategies of hepatitis B virus reactivation in patients with resolved hepatitis virus B infection undergoing immunosuppressive therapy in rheumatology and the current situation in Niigata Rheumatic Center.
Ito S
Mod Rheumatol; 2021 Jul; 31(4):775-782. PubMed ID: 33021133
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
